Keyphrases
In Vitro Susceptibility
100%
PA-824
100%
Pyrazinamide
30%
Plasma Concentration
10%
Tuberculosis Treatment
10%
In Silico Modeling
10%
Moxifloxacin
10%
Anti-tuberculosis Drugs
10%
Proportion Method
10%
Complex Genotype
10%
Mycobacterium Canettii
10%
BACTEC MGIT 960
10%
Phase II Clinical Trial
10%
Promising Drug
10%
New Regimen
10%
MGIT 960
10%
Biochemistry, Genetics and Molecular Biology
Minimum Inhibitory Concentration
100%
Mycobacterium Tuberculosis Complex
100%
Genotyping
40%
Single-Nucleotide Polymorphism
20%
Genetic Divergence
20%
Phylogeny
20%
Computer Model
20%
Mycobacterium
20%
Blood Level
20%
Immunology and Microbiology
Minimum Inhibitory Concentration
100%
Mycobacterium Tuberculosis Complex
100%
Mycobacteria
20%
Lineages
20%
Genetic Variability
20%
Phylogeny
20%
Single Nucleotide Polymorphism
20%
Computer Model
20%
Blood Level
20%
Pharmacology, Toxicology and Pharmaceutical Science
Mycobacterium Tuberculosis Complex
100%
Pyrazinamide
75%
Moxifloxacin
25%
Infection
25%
Mycobacterium
25%
Tuberculostatic Agent
25%